Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
INFAI is a biotechnology company specializing in the development of non-invasive diagnostic tools using stable isotope technology. The company's primary product, Helicobacter Test INFAI, is a gold-standard 13C-urea breath test used globally for the detection of Helicobacter pylori infections. In addition to gastric diagnostics, INFAI offers a portfolio of breath tests for assessing pancreatic function, gastric emptying, and various metabolic disorders. The company provides integrated solutions including diagnostic kits and high-precision analytical services via isotope ratio mass spectrometry. Headquartered in Germany, INFAI maintains a strong international presence through subsidiaries and partnerships across Europe and Asia. Their technology platform focuses on the use of non-radioactive 13C-labeled substrates to monitor enzymatic activity and metabolic pathways in vivo.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Helicobacter Test INFAI.